Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04578600 · ClinicalTrials.gov registry record · Phase 1
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
A Phase 1 study, sponsored by Joseph Tuscano.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04578600 is a Phase 1 study that has completed, run by Joseph Tuscano. The registered enrollment target is 8 participants.
The verdict
NCT04578600, a Phase 1 study, has completed, sponsored by Joseph Tuscano.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I/Ib trial investigates the side effects of CC-486 and how well it works in combination with lenalidomide and obinutuzumab in treating patients with CD20 positive B-cell lymphoma that has come back (recurrent) or has not responded to treatment (refractory). Chemotherapy drugs, such as CC-486, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide is a drug that alters the immune system and may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Obinutuzumab is a type of antibody therapy that targets and attaches to the CD20 proteins found on follicular lymphoma cells as well as some healthy blood cells. Once attached to the CD20 protein the obinutuzumab is thought to work in different ways, including by helping the immune system destroy the cancer cells and by destroying the cancer cells directly. Giving CC-486 with lenalidomide and obinutuzumab may improve response rates, quality, and duration, and minimize adverse events in patients with B-cell lymphoma.
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Obinutuzumab
- DRUG Oral Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2025-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04578600
The ClinicalTrials.gov registry entry for NCT04578600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joseph Tuscano, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide is the first listed.
NCT04578600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04578600 about?
NCT04578600 is a clinical study titled "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma". This phase I/Ib trial investigates the side effects of CC-486 and how well it works in combination with lenalidomide and obinutuzumab in treating patients with CD20 positive B-cell lymphoma that has come back (recurrent) or has not responded to treatment (refractory). Chemotherapy drugs, such as CC-...
What is the current status of trial NCT04578600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-10-23. Estimated completion is 2025-02-21.
What interventions are being tested in trial NCT04578600?
The interventions under investigation include: Lenalidomide (DRUG), Obinutuzumab (BIOLOGICAL), Oral Azacitidine (DRUG).
Who is sponsoring clinical trial NCT04578600?
This trial is sponsored by Joseph Tuscano, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.